Identification

Name
Chlorpromazine
Accession Number
DB00477  (APRD00482)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.

Structure
Thumb
Synonyms
  • 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
  • 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
  • Chlorpromazinum
  • Clorpromazina
  • CPZ
  • N-(3-dimethylaminopropyl)-3-chlorophenothiazine
External IDs
J2.794D / NSC-167745 / NSC-226514
Product Ingredients
IngredientUNIICASInChI Key
Chlorpromazine hydrochloride9WP59609J669-09-0FBSMERQALIEGJT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorprom Tab 100mgTablet111.6 mgOralIcn Pharmaceuticals1962-12-311998-08-13Canada
Chlorprom Tab 25mgTablet27.9 mgOralIcn Pharmaceuticals1974-12-311998-08-13Canada
Chlorprom Tab 50mgTablet55.8 mgOralIcn Pharmaceuticals1962-12-311998-08-13Canada
Chlorpromanyl 20 SyrSolution / drops22.2 mgOralTechnilab Pharma Inc.1983-12-312004-08-03Canada
Chlorpromanyl 40 Drops Syr 44.5mg/mlSyrup44.5 mgOralTechnilab Pharma Inc.1986-12-312006-07-28Canada
Chlorpromazine HCl Inj 25mg/ml USPLiquid25 mgIntramuscular; IntravenousMylan Pharmaceuticals1994-12-312015-11-03Canada
Chlorpromazine HCl Inj 27.9mg/mlLiquid27.9 mgIntramuscular; IntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311996-09-10Canada
Chlorpromazine HCl Inj USPSolution25 mgIntramuscular; IntravenousAlveda Pharmaceuticals IncNot applicableNot applicableCanada
Chlorpromazine Hydrochloride InjectionLiquid27.9 mgIntramuscular; IntravenousSandoz Canada Incorporated1988-12-31Not applicableCanada
Chlorpromazine Tab 25mgTablet27.9 mgOralDuchesnay Inc.1978-12-312003-07-18Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo ChlorpromazineTablet111.4 mgOralApotex Corporation1976-12-312011-08-05Canada
Apo ChlorpromazineTablet55.7 mgOralApotex Corporation1976-12-312011-08-05Canada
Apo ChlorpromazineTablet27.9 mgOralApotex Corporation1976-12-312011-08-05Canada
ChlorpromazineTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs00781 1718 01 nlmimage10 7d04bef5
ChlorpromazineTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
ChlorpromazineTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralTYA Pharmaceuticals1974-07-09Not applicableUs
Chlorpromazine HydrochlorideTablet, sugar coated100 mg/1OralRemedy Repack2010-12-162017-01-18Us
Chlorpromazine HydrochlorideTablet, sugar coated200 mg/1OralClinical Solutions Wholsesale2011-08-032017-06-20Us
Chlorpromazine HydrochlorideTablet, sugar coated25 mg/1OralRemedy Repack2007-05-042017-07-27Us
International/Other Brands
Aminazine / Chlorderazin / Chloropromazine / Chlorpromados / Chlorpromanyl (Technilab (Canada)) / Contomin / Largactil (Specia) / Thorazine (GlaxoSmithKline)
Categories
UNII
U42B7VYA4P
CAS number
50-53-3
Weight
Average: 318.864
Monoisotopic: 318.095747015
Chemical Formula
C17H19ClN2S
InChI Key
ZPEIMTDSQAKGNT-UHFFFAOYSA-N
InChI
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
IUPAC Name
[3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2

Pharmacology

Indication

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Structured Indications
Pharmacodynamics

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.

Mechanism of action

Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use).

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 1A
antagonist
Human
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
AHistamine H1 receptor
antagonist
Human
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
UD(1) dopamine receptorNot AvailableHuman
UD(3) dopamine receptorNot AvailableHuman
UD(4) dopamine receptor
binder
Human
UD(1B) dopamine receptorNot AvailableHuman
U5-hydroxytryptamine receptor 2C
binder
Human
U5-hydroxytryptamine 2 receptor
binder
Human
UAlpha-1 adrenergic receptorsNot AvailableHuman
UAlpha-2 adrenergic receptorsNot AvailableHuman
UMuscarinic acetylcholine receptor M1Not AvailableHuman
UMuscarinic acetylcholine receptor M3Not AvailableHuman
USphingomyelin phosphodiesteraseNot AvailableHuman
UCalmodulinNot AvailableHuman
Ualpha1-acid glycoprotein
binder
Human
U5-hydroxytryptamine receptor 6
binder
Human
U5-hydroxytryptamine receptor 7
binder
Human
UHistamine H4 receptor
binder
Human
Absorption

Readily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver.

Volume of distribution
  • 20 L/kg
Protein binding

> 90% to plasma proteins, primarily albumin

Metabolism

Extensively metabolized in the liver and kidneys. It is extensively metabolized by cytochrome P450 isozymes CYP2D6 (major pathway), CYP1A2 and CYP3A4. Approximately 10 to 12 major metabolite have been identified. Hydroxylation at positions 3 and 7 of the phenothiazine nucleus and the N-dimethylaminopropyl side chain undergoes demethylation and is also metabolized to an N-oxide. In urine, 20% of chlopromazine and its metabolites are excreted unconjugated in the urine as unchanged drug, demonomethylchlorpromazine, dedimethylchlorpromazine, their sulfoxide metabolites, and chlorpromazine-N-oxide. The remaining 80% consists of conjugated metabolites, principally O-glucuronides and small amounts of ethereal sulfates of the mono- and dihydroxy-derivatives of chlorpromazine and their sulfoxide metabolites. The major metabolites are the monoglucuronide of N-dedimethylchlorpromazine and 7-hydroxychlorpromazine. Approximately 37% of the administered dose of chlorpromazine is excreted in urine.

Route of elimination

Kidneys, ~ 37% excreted in urine

Half life

~ 30 hours

Clearance
Not Available
Toxicity

Agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineChlorpromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineChlorpromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineChlorpromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Chlorpromazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Chlorpromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Chlorpromazine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Chlorpromazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Chlorpromazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorpromazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Chlorpromazine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Chlorpromazine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Chlorpromazine.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorpromazine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Chlorpromazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Chlorpromazine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Chlorpromazine.Approved, Withdrawn
AmiodaroneThe metabolism of Chlorpromazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Chlorpromazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Chlorpromazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Chlorpromazine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorpromazine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Chlorpromazine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Chlorpromazine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amyl Nitrite.Approved
AnagrelideChlorpromazine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Chlorpromazine.Approved
ApomorphineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Chlorpromazine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Chlorpromazine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Chlorpromazine.Approved, Investigational
ArotinololChlorpromazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Chlorpromazine.Approved, Investigational
ArtemetherThe serum concentration of Chlorpromazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Chlorpromazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Chlorpromazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Chlorpromazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Chlorpromazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Chlorpromazine.Approved, Withdrawn
AtazanavirThe metabolism of Chlorpromazine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Chlorpromazine.Approved
AtovaquoneThe serum concentration of Chlorpromazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Azaperone.Investigational, Vet Approved
AzelastineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Azilsartan medoxomil.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Chlorpromazine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Chlorpromazine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Chlorpromazine.Approved
BedaquilineChlorpromazine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololChlorpromazine may increase the hypotensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Chlorpromazine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benzocaine.Approved
BenzphetamineChlorpromazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Chlorpromazine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Chlorpromazine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Chlorpromazine.Approved
BevantololChlorpromazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideChlorpromazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Chlorpromazine.Approved
BoceprevirThe metabolism of Chlorpromazine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololChlorpromazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
BosentanThe serum concentration of Chlorpromazine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorpromazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpromazine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Chlorpromazine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Chlorpromazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololChlorpromazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Chlorpromazine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Chlorpromazine.Approved, Investigational
BupranololChlorpromazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Chlorpromazine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Chlorpromazine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Chlorpromazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorpromazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorpromazine.Approved
CaffeineThe metabolism of Chlorpromazine can be decreased when combined with Caffeine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Canertinib.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Captopril.Approved
CarbamazepineThe metabolism of Chlorpromazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorpromazine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Chlorpromazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carisoprodol.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Chlorpromazine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Chlorpromazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololChlorpromazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CeritinibThe serum concentration of Chlorpromazine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Chlorpromazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Chlorpromazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloroprocaine.Approved
ChloroquineChlorpromazine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Chlorpromazine.Approved
ChlorphentermineChlorpromazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Chlorpromazine.Approved
CholecalciferolThe metabolism of Chlorpromazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Cholic AcidChlorpromazine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cilnidipine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Chlorpromazine.Approved
CimetidineThe metabolism of Chlorpromazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Chlorpromazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Chlorpromazine.Approved, Investigational
CiprofloxacinChlorpromazine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideChlorpromazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Chlorpromazine can be decreased when combined with Citalopram.Approved
ClarithromycinChlorpromazine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Chlorpromazine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Chlorpromazine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clidinium.Approved
ClobazamThe metabolism of Chlorpromazine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clopenthixol.Experimental
CloranololChlorpromazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Chlorpromazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Chlorpromazine.Approved
CobicistatThe serum concentration of Chlorpromazine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Chlorpromazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chlorpromazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorpromazine.Approved
ConivaptanThe serum concentration of Chlorpromazine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibChlorpromazine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.Approved
Cycloguanil embonateThe serum concentration of Chlorpromazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Chlorpromazine.Approved, Investigational
CyclosporineThe metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Chlorpromazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpromazine.Approved
DabrafenibThe serum concentration of Chlorpromazine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Chlorpromazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Chlorpromazine.Approved, Investigational
DarunavirThe serum concentration of Chlorpromazine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Chlorpromazine.Approved
DasatinibThe serum concentration of Chlorpromazine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Chlorpromazine.Approved, Investigational
DeferasiroxThe serum concentration of Chlorpromazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Chlorpromazine.Approved
DelavirdineThe metabolism of Chlorpromazine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorpromazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Chlorpromazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Chlorpromazine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Chlorpromazine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Chlorpromazine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Chlorpromazine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Chlorpromazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Diethyl ether.Experimental
DiethylpropionChlorpromazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Chlorpromazine.Approved, Illicit
DihydroergotamineThe metabolism of Chlorpromazine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Chlorpromazine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dipyridamole.Approved
DisopyramideChlorpromazine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dixyrazine.Experimental
DofetilideChlorpromazine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronChlorpromazine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Chlorpromazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Chlorpromazine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Chlorpromazine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Chlorpromazine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpromazine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Chlorpromazine.Approved, Investigational
DoxycyclineThe serum concentration of Chlorpromazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Illicit
DronedaroneThe metabolism of Chlorpromazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Drotebanol.Experimental, Illicit
DuloxetineChlorpromazine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorpromazine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Chlorpromazine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Chlorpromazine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Chlorpromazine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Chlorpromazine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Chlorpromazine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Chlorpromazine can be decreased when it is combined with Enzalutamide.Approved
EpanololChlorpromazine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Chlorpromazine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpromazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorpromazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorpromazine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Chlorpromazine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Chlorpromazine.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Chlorpromazine.Investigational
EsmololChlorpromazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorpromazine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etacrynic acid.Approved
EthanolChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Chlorpromazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Chlorpromazine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorpromazine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Chlorpromazine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Chlorpromazine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Chlorpromazine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorpromazine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fimasartan.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
FlecainideChlorpromazine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Chlorpromazine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Chlorpromazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Chlorpromazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Chlorpromazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Chlorpromazine.Approved
FluvoxamineThe metabolism of Chlorpromazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
FosamprenavirThe metabolism of Chlorpromazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Chlorpromazine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Chlorpromazine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Chlorpromazine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Chlorpromazine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Chlorpromazine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gabapentin Enacarbil.Approved
Gadobenic acidChlorpromazine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Chlorpromazine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Chlorpromazine.Approved, Investigational
GemifloxacinChlorpromazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineChlorpromazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Chlorpromazine.Approved
GranisetronChlorpromazine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Chlorpromazine can be increased when it is combined with Halofantrine.Approved
HaloperidolChlorpromazine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Chlorpromazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Chlorpromazine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Chlorpromazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineChlorpromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Chlorpromazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Chlorpromazine.Approved
IbutilideChlorpromazine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Chlorpromazine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Chlorpromazine.Approved
IloprostThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Chlorpromazine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Chlorpromazine.Approved
IndenololChlorpromazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Chlorpromazine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indoramin.Withdrawn
Iofetamine I-123Chlorpromazine may decrease the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Chlorpromazine.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Chlorpromazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorpromazine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
IsoniazidThe metabolism of Chlorpromazine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Chlorpromazine.Approved
ItraconazoleThe metabolism of Chlorpromazine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Chlorpromazine.Approved
IvacaftorThe serum concentration of Chlorpromazine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Chlorpromazine.Approved
KetamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Chlorpromazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Chlorpromazine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lamotrigine.Approved, Investigational
LandiololChlorpromazine may increase the hypotensive activities of Landiolol.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorpromazine.Approved
LenvatinibChlorpromazine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lercanidipine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Chlorpromazine.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levetiracetam.Approved, Investigational
LevobunololChlorpromazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levocetirizine.Approved
LevodopaChlorpromazine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinChlorpromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Chlorpromazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levosimendan.Approved, Investigational
LidocaineThe metabolism of Chlorpromazine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorpromazine.Approved, Investigational
LisdexamfetamineChlorpromazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Chlorpromazine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Chlorpromazine.Approved
LobeglitazoneThe metabolism of Chlorpromazine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Chlorpromazine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Chlorpromazine.Approved
LopinavirThe metabolism of Chlorpromazine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Loprazolam.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Chlorpromazine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorpromazine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Chlorpromazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Losartan.Approved
LovastatinThe metabolism of Chlorpromazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorpromazine.Approved
LuliconazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Chlorpromazine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Chlorpromazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Chlorpromazine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Chlorpromazine.Approved
MebicarThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Chlorpromazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Melperone.Approved, Investigational
MephedroneChlorpromazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineChlorpromazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Chlorpromazine.Investigational, Withdrawn
MepindololChlorpromazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorpromazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Meptazinol.Experimental
MequitazineChlorpromazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Chlorpromazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Chlorpromazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Chlorpromazine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorpromazine.Approved
MethotrimeprazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
MethoxyphenamineChlorpromazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Chlorpromazine.Approved, Illicit, Withdrawn
MetipranololChlorpromazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorpromazine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Chlorpromazine.Approved
MetyrosineChlorpromazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Chlorpromazine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Chlorpromazine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Midazolam.Approved, Illicit
MidomafetamineChlorpromazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Chlorpromazine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Chlorpromazine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Chlorpromazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Minoxidil.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Chlorpromazine.Approved
MirtazapineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Chlorpromazine can be decreased when it is combined with Mitotane.Approved
MizoribineThe serum concentration of Chlorpromazine can be increased when it is combined with Mizoribine.Investigational
MMDAChlorpromazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Chlorpromazine.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Chlorpromazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorpromazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorpromazine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Chlorpromazine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Chlorpromazine.Approved, Investigational
NefazodoneThe metabolism of Chlorpromazine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Chlorpromazine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Chlorpromazine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Chlorpromazine can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Chlorpromazine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Chlorpromazine.Approved, Investigational
NicomorphineChlorpromazine may increase the hypotensive activities of Nicomorphine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Chlorpromazine.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Chlorpromazine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nifedipine.Approved
NilotinibThe metabolism of Chlorpromazine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitric Oxide.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Chlorpromazine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
OfloxacinChlorpromazine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
OlaparibThe metabolism of Chlorpromazine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olopatadine.Approved
OndansetronChlorpromazine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Opium.Approved, Illicit
OrphenadrineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Chlorpromazine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxybuprocaine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Chlorpromazine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Chlorpromazine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Chlorpromazine.Approved, Investigational
PanobinostatThe serum concentration of Chlorpromazine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Papaverine.Approved
ParaldehydeChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Chlorpromazine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Chlorpromazine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorpromazine.Approved
Peginterferon alfa-2bThe serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololChlorpromazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Penfluridol.Experimental
PentamidineChlorpromazine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Chlorpromazine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perazine.Investigational
PerflutrenChlorpromazine may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Chlorpromazine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Chlorpromazine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Chlorpromazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Chlorpromazine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorpromazine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Chlorpromazine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Chlorpromazine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenoxyethanol.Approved
PhentermineChlorpromazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phentolamine.Approved
PhenytoinThe metabolism of Chlorpromazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Chlorpromazine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pipamperone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Chlorpromazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pizotifen.Approved
Platelet Activating FactorChlorpromazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Chlorpromazine.Approved
PosaconazoleThe metabolism of Chlorpromazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololChlorpromazine may increase the hypotensive activities of Practolol.Approved
PramipexoleChlorpromazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorpromazine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prilocaine.Approved
PrimaquineChlorpromazine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Chlorpromazine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Chlorpromazine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorpromazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ProguanilThe serum concentration of Chlorpromazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Chlorpromazine.Approved
PropafenoneThe serum concentration of Chlorpromazine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorpromazine.Approved
PSD502The risk or severity of adverse effects can be increased when Chlorpromazine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Chlorpromazine.Approved
PyrimethamineThe serum concentration of Chlorpromazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Chlorpromazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorpromazine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Chlorpromazine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Chlorpromazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Chlorpromazine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorpromazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorpromazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Chlorpromazine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Chlorpromazine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Reserpine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Chlorpromazine.Approved
RifabutinThe metabolism of Chlorpromazine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Chlorpromazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Chlorpromazine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorpromazine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Chlorpromazine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Riociguat.Approved
RisperidoneChlorpromazine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ritanserin.Investigational
RitobegronChlorpromazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Chlorpromazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorpromazine.Approved
RolapitantThe metabolism of Chlorpromazine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Romifidine.Vet Approved
RopiniroleChlorpromazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Chlorpromazine.Approved
RotigotineChlorpromazine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Chlorpromazine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorpromazine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Chlorpromazine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
SaquinavirChlorpromazine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorpromazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sepranolone.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Chlorpromazine.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Chlorpromazine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
SildenafilThe metabolism of Chlorpromazine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorpromazine.Approved
SiltuximabThe serum concentration of Chlorpromazine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Chlorpromazine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Chlorpromazine.Approved
SinefunginThe serum concentration of Chlorpromazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Chlorpromazine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Chlorpromazine.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Chlorpromazine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Chlorpromazine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Chlorpromazine.Approved
SulfametopyrazineThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Chlorpromazine.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
SuvorexantChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Chlorpromazine can be increased when it is combined with tafenoquine.Investigational
TalinololChlorpromazine may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chlorpromazine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Chlorpromazine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorpromazine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Chlorpromazine.Investigational, Withdrawn
TelaprevirThe metabolism of Chlorpromazine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinChlorpromazine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinChlorpromazine may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorpromazine.Approved
Tenofovir disoproxilThe metabolism of Chlorpromazine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Terazosin.Approved
TerbinafineThe metabolism of Chlorpromazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Chlorpromazine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Chlorpromazine.Withdrawn
TeriflunomideThe serum concentration of Chlorpromazine can be decreased when it is combined with Teriflunomide.Approved
TertatololChlorpromazine may increase the hypotensive activities of Tertatolol.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Chlorpromazine.Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorpromazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetrodotoxin.Investigational
ThalidomideChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Chlorpromazine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Chlorpromazine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Chlorpromazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Chlorpromazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Timolol.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Chlorpromazine.Approved
TipranavirThe metabolism of Chlorpromazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Chlorpromazine.Approved
TocilizumabThe serum concentration of Chlorpromazine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorpromazine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Torasemide.Approved
ToremifeneChlorpromazine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Chlorpromazine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chlorpromazine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Chlorpromazine can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Chlorpromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
TromethamineTromethamine can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Chlorpromazine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Chlorpromazine.Approved, Investigational
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Chlorpromazine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Valsartan.Approved, Investigational
VandetanibChlorpromazine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Chlorpromazine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Chlorpromazine.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Chlorpromazine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Veralipride.Experimental
VerapamilThe metabolism of Chlorpromazine can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Chlorpromazine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Chlorpromazine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Chlorpromazine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Chlorpromazine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorpromazine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Chlorpromazine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Chlorpromazine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Chlorpromazine.Approved
XenonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Chlorpromazine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Chlorpromazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorpromazine.Approved, Investigational
ZolpidemChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Chlorpromazine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Chlorpromazine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Charpentier, P.; U S . Patent 2,645,640; July 14, 1953; assigned to Societe des Usines Chimiques Rhone-Poulenc, France.

US2645640
General References
  1. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10;361(9369):1581-9. [PubMed:12747876]
External Links
Human Metabolome Database
HMDB14620
KEGG Drug
D00270
KEGG Compound
C06906
PubChem Compound
2726
PubChem Substance
46508395
ChemSpider
2625
BindingDB
50001888
ChEBI
3647
ChEMBL
CHEMBL71
Therapeutic Targets Database
DAP000374
PharmGKB
PA448964
IUPHAR
83
Guide to Pharmacology
GtP Drug Page
HET
Z80
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Chlorpromazine
ATC Codes
N05AA01 — Chlorpromazine
AHFS Codes
  • 28:16.08.24 — Phenothiazines
PDB Entries
3apx / 3lk0 / 4ma8 / 5g08 / 5lg3
MSDS
Download (75.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceAcute Intermittent Porphyria (AIP) / Adjunct in the Treatment of Tetanus / Anti-Psychotic / Control Manifestations of the Manic Type of Mani-depressive Illness / Control Nausea and Vomiting / Management of Manifestations of Psychotic Disorders / Relief of Intractable Hiccups / Relief of Restlessness and Apprehension Before Surgery / Treatment of Schizophrenia1
2, 3RecruitingTreatmentMalignant Neoplasms of Independent (Primary) Multiple Sites1
3CompletedTreatmentDrug withdrawal syndrome neonatal1
3CompletedTreatmentSchizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4CompletedTreatmentSchizophrenic Disorders1
4RecruitingTreatmentBipolar Disorder (BD) / Schizoaffective Disorders1
4TerminatedTreatmentSchizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedSupportive CareBlind Painful Eye / Control of Pain Through Drug Injection / Refractory Glaucoma1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Actavis mid atlantic llc
  • Pharmaceutical assoc inc div beach products
  • Wockhardt eu operations (swiss) ag
  • Roxane laboratories inc
  • Sandoz inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Marsam pharmaceuticals llc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Alpharma us pharmaceuticals division
  • Abbott laboratories pharmaceutical products div
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lederle laboratories div american cyanamid co
  • Purepac pharmaceutical co
  • Private formulations inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • West ward pharmaceutical corp
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
TabletOral111.4 mg
TabletOral55.7 mg
TabletOral111.6 mg
TabletOral27.9 mg
TabletOral55.8 mg
Solution / dropsOral22.2 mg
SyrupOral44.5 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
LiquidIntramuscular; Intravenous25 mg
SolutionIntramuscular; Intravenous25 mg
InjectionIntramuscular25 mg/mL
TabletOral200 mg/1
TabletOral50 mg/1
Tablet, film coatedOral25 mg/1
Tablet, sugar coatedOral10 mg/1
Tablet, sugar coatedOral100 mg/1
Tablet, sugar coatedOral200 mg/1
Tablet, sugar coatedOral25 mg/1
Tablet, sugar coatedOral50 mg/1
LiquidIntramuscular; Intravenous27.9 mg
TabletOral25 mg
TabletOral50 mg
LiquidOral100 mg
LiquidOral25 mg
SolutionIntramuscular; Intravenous50 mg
Solution / dropsOral40 mg
SuppositoryRectal100 mg
TabletOral223.2 mg
TabletOral11.16 mg
TabletOral100 mg
TabletOral25.0 mg
TabletOral50.0 mg
Prices
Unit descriptionCostUnit
Chlorpromazine 25 mg/ml amp8.04USD ml
ChlorproMAZINE HCl 200 mg tablet1.19USD tablet
Chlorpromazine 200 mg tablet1.05USD tablet
ChlorproMAZINE HCl 100 mg tablet0.84USD tablet
ChlorproMAZINE HCl 50 mg tablet0.73USD tablet
ChlorproMAZINE HCl 25 mg tablet0.55USD tablet
Chlorpromazine 100 mg tablet0.39USD tablet
ChlorproMAZINE HCl 10 mg tablet0.37USD tablet
Chlorpromazine 10 mg tablet0.32USD tablet
Chlorpromazine 50 mg tablet0.3USD tablet
Chlorpromazine 25 mg tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)177-178Charpentier, P.; U S . Patent 2,645,640; July 14, 1953; assigned to Societe des Usines Chimiques Rhone-Poulenc, France
boiling point (°C)200-205 °C at 8.00E-01 mm HgPhysProp
water solubility2.55 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.41AVDEEF,A (1995)
logS-5.01ADME Research, USCD
Caco2 permeability-4.7ADME Research, USCD
pKa9.3 (at 25 °C)HANSCH,C & LEO,AJ (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00417 mg/mLALOGPS
logP5.18ALOGPS
logP4.54ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.76 m3·mol-1ChemAxon
Polarizability35.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9757
Blood Brain Barrier+0.9795
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.787
P-glycoprotein inhibitor IInhibitor0.7164
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.7557
CYP450 2C9 substrateNon-substrate0.7617
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6477
CYP450 1A2 substrateInhibitor0.9305
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.9422
CYP450 2C19 inhibitorInhibitor0.5512
CYP450 3A4 inhibitorNon-inhibitor0.9375
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6601
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9309
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3196 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9536
hERG inhibition (predictor II)Inhibitor0.787
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.36 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4r-9053000000-9e1cc1d4fc6be5bc73b8
GC-MS Spectrum - CI-BGC-MSsplash10-014i-2019000000-54e008f9fc11d7f45b68
GC-MS Spectrum - CI-BGC-MSsplash10-000i-9070000000-9bbe6c5123c891b9489b
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9231000000-ed14fee152701eacf689
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0019000000-0028b3984b4c35e44def
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-800bf68c2158920c3f30
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03dj-0090000000-649e773296a3ecec2b04
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0190000000-7404aac4e28621b4f60a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01b9-0019000000-993566c51e802e754da2

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Benzenoids / Aryl chlorides / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Aryl chloride / Aryl halide / Benzenoid / Tertiary aliphatic amine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amine, organochlorine compound (CHEBI:3647)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  3. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263]
  4. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630]
  7. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055]
  8. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl). 1995 Aug;120(3):365-8. [PubMed:8524985]
Details
2. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134]
  2. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
Details
7. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
  2. Church MK, Young KD: The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol. 1983 Apr;78(4):671-9. [PubMed:6189542]
  3. Johnson HG, Miller MD: Inhibition of histamine release and ionophore-induced calcium flux in rat mast cells by lidocaine and chlorpromazine. Agents Actions. 1979 Aug;9(3):239-43. [PubMed:91313]
  4. Palmer GC, Wagner HR, Palmer SJ, Manian AA: Histamine-, norepinephrine-, and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine derivatives and butaclamol. Arch Int Pharmacodyn Ther. 1978 Jun;233(2):314-25. [PubMed:687395]
  5. Ruffolo RR, Patil PN: Kinetics of blockade of different receptors by chlorpromazine in rabbit stomach strips. Eur J Pharmacol. 1978 Mar 15;48(2):151-7. [PubMed:25190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Thomas D, Wu K, Kathofer S, Katus HA, Schoels W, Kiehn J, Karle CA: The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol. 2003 Jun;139(3):567-74. [PubMed:12788816]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993 Aug;6(4):602-8. [PubMed:8104554]
Details
10. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl). 1995 Aug;120(3):365-8. [PubMed:8524985]
Details
12. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993 Aug;6(4):602-8. [PubMed:8104554]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...

Components:
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA: Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70. [PubMed:6135146]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Bylund DB, Ray-Prenger C, Murphy TJ: Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther. 1988 May;245(2):600-7. [PubMed:2835476]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl). 2005 Apr;178(4):451-60. Epub 2004 Oct 13. [PubMed:15765260]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl). 2005 Apr;178(4):451-60. Epub 2004 Oct 13. [PubMed:15765260]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sphingomyelin phosphodiesterase activity
Specific Function
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic ac...
Gene Name
SMPD1
Uniprot ID
P17405
Uniprot Name
Sphingomyelin phosphodiesterase
Molecular Weight
69751.3 Da
References
  1. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M, Satoyoshi E: Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem. 1985 Dec;98(6):1669-79. [PubMed:2419314]
Details
20. Calmodulin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Marshak DR, Lukas TJ, Watterson DM: Drug-protein interactions: binding of chlorpromazine to calmodulin, calmodulin fragments, and related calcium binding proteins. Biochemistry. 1985 Jan 1;24(1):144-50. [PubMed:2986673]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055]
Details
24. Histamine H4 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Histamine receptor activity
Specific Function
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agoni...
Gene Name
HRH4
Uniprot ID
Q9H3N8
Uniprot Name
Histamine H4 receptor
Molecular Weight
44495.375 Da
References
  1. Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF: Discovery of a novel member of the histamine receptor family. Mol Pharmacol. 2001 Mar;59(3):427-33. [PubMed:11179435]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273]
  3. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K: Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000;67(2):175-84. [PubMed:10901285]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K: Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000;67(2):175-84. [PubMed:10901285]
  2. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Nasello AG, Gidali D, Felicio LF: A comparative study of the anticholinesterase activity of several antipsychotic agents. Pharmacol Biochem Behav. 2003 Jul;75(4):895-901. [PubMed:12957233]
  2. Muraoka S, Miura T: Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003 Feb;92(2):100-4. [PubMed:12747580]
  3. Spinedi A, Pacini L, Limatola C, Luly P, Farias RN: A study of human erythrocyte acetylcholinesterase inhibition by chlorpromazine. Biochem J. 1991 Sep 1;278 ( Pt 2):461-3. [PubMed:1654884]

Carriers

Details
1. Serum albumin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  2. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]
Details
3. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18